VX 993
Alternative Names: VX-993Latest Information Update: 15 Oct 2024
At a glance
- Originator Vertex Pharmaceuticals
- Class Analgesics
- Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pain
Most Recent Events
- 01 Oct 2024 Vertex pharmaceuticals plans a phase II trial for Neuropathic pain (PO) (NCT06619860)
- 01 Oct 2024 Vertex Pharmaceuticals Incorporated plans a phase II trial for Pain in October 2024 (NCT06619847)
- 31 Jul 2024 Vertex Pharmaceuticals initiates a phase I trial for Pain (In volunteers) in USA (PO) (NCT06523595)